
Asston Pharmaceuticals Limited - IPO
SMEAsston Pharmaceuticals IPO Details
Asston Pharmaceuticals IPO Subscription
Asston Pharmaceuticals IPO Application Wise Breakup
Asston Pharmaceuticals IPO Dates
- 09 Jul 2025Opening dateOPD
- 11 Jul 2025Closing dateCOD
- 14 Jul 2025Basis of AllotmentBOA
- 15 Jul 2025Initiation of RefundsIOR
- 15 Jul 2025Credit of SharesCOS
- 16 Jul 2025Listing dateLID
Asston Pharmaceuticals IPO Lot Size
Application | Lots | Shares | Amount |
---|---|---|---|
Individual Minimum | 2 | 2000 | ₹246,000 |
Individual Maximum | 2 | 2000 | ₹246,000 |
SHNI Minimum | 3 | 3000 | ₹369,000 |
SHNI Maximum | 8 | 8000 | ₹984,000 |
BHNI Minimum | 9 | 9000 | ₹1,107,000 |
Asston Pharmaceuticals IPO Reservation
Promoter Holding
Asston Pharmaceuticals IPO Valuations
Asston Pharmaceuticals Limited Financial Information
Period Ended | 31 May 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
Assets | 31.83 | 28.12 | 20.26 | 13.69 |
Revenue | 6.21 | 25.61 | 15.84 | 7.19 |
Profit After Tax | 1.32 | 4.33 | 1.36 | 1.06 |
EBITDA | 1.93 | 6.16 | 2.55 | 1.52 |
Net Worth | 12.04 | 10.72 | 6.39 | 1.99 |
Reserves and Surplus | 5.77 | 4.45 | 5.61 | 1.29 |
Total Borrowing | 7.83 | 7.26 | 6.82 | 5.25 |
Amount in ₹ Crore |
About Asston Pharmaceuticals IPO
Incorporated in 2019, Asston Pharmaceuticals Limited is engaged in the business of pharmaceuticals, specializing in exporting healthcare products globally.
The company offers a diverse range of products, including tablets, capsules, sachets, and syrups. Its product portfolio encompasses various therapeutic categories, such as analgesics, antibiotics, antifungals, vitamins, and more.
The company manufactures pharmaceutical products for direct sales and also on a contract manufacturing or loan license basis, primarily working on a principle-to-principle approach with various marketers.
The company is FDA certified by both Central and State FDA, accredited by NQA (Nuclear Quality Assurance), and complies with Quality Management System (QMS) standards, ensuring high-quality manufacturing.
Products:
- Albendazole USP 400 mg: Albendazole USP 400 mg refers to a higher dosage of Albendazole, a broad-spectrum anthelmintic (anti-worm) medication that is used to treat various parasitic worm infections.
- Diclofenac 100 mg: Diclofenac 100 mg refers to a specific dosage of Diclofenac, a widely used nonsteroidal anti-inflammatory drug (NSAID).
- Ibuprofen, paracetamol: Ibuprofen and Paracetamol (Acetaminophen) are two commonly used over-the-counter medications, often used to relieve pain and reduce fever.
- Ferrovit Syrup: To treat vitamin and mineral deficiencies.
As of 3 July 2025, the company has 46 Permanent employees and 6 contractual employees in various departments.
Strength Of Asston Pharmaceuticals IPO
1. Formulation Expertise.
2. Experienced Promoters.
3. Wide range of Products.
4. Strategic Location.
5. Skilled Workforce.
6. Good relationship with contract manufacturers.
7. Quality Assurance.
8. Good relationship with clients in the export market.
9. Competitive Pricing.
10. Asset Light Model.
Risk Of Asston Pharmaceuticals IPO
1. The Company operates in pharmaceutical sector, which is extensively regulated, any failures on its part to comply with the existing and future statutory and/or regulatory requirements in the pharmaceutical sector could adversely affect its business, results of operations and financial condition.
2. The company operate its own manufacturing facility for pharmaceutical products; however for certain products other than tablets, the company relies on third-party manufacturers to procure the pharmaceutical products.
3. The company depends on the success of its relationships with the company customers. The company derives a significant part of its revenue from its major customers and the company does not have long-term contracts with these customers other than contracts with 2 customers for one year. If one or more of such customers choose not to source their requirements from it, the company business, financial condition and results of operations may be adversely affected.
4. The loss of contract manufacturing tie-ups and the low entry barrier for contract manufacturing can affect production, order intake, revenue, cash flow, and profitability. The absence of exclusive agreements increases the risk of delays or disruptions in order execution, further impacting business operations.
5. The company has substantial working capital expenditure and may requires additional financing to meet those requirements and have risk of receivables, which could have an adverse effect on its results of operations and financial condition.
6. The property used by the Company for the purpose of its Registered Office and factory is not owned by the company. Any termination of the relevant lease agreement in connection with such property or the company failures to renew the same could adversely affect its operations.
7. The company success largely depends upon the knowledge and experience of its Promoters, Directors, the company Key Managerial Personnel and Senior Management as well as its ability to attract and retain personnel with technical expertise. Any loss of the company Promoter, Directors, Key Managerial Personnel, Senior Management or its ability to attract and retain them and other personnel with technical expertise could adversely affect its business, financial condition and results of operations.
8. If the company is not able to attract and retain sufficient qualified and trained personnel at the Company which may adversely affect its business.
9. The company has been recently converted into public limited company and any non-compliance with the provisions of Companies Act, 2013 may attract penalties against the Company which could impact its financial and operational performance and reputation.
10. All its manufacturing facilities are situated at Ambernath, Thane, Maharashtra resulting in concentration in a single region. Any interruption for a significant period of time, in these facilities may in turn adversely affect its business, financial condition and results of operations.
Objectives Asston Pharmaceuticals IPO
1. Funding capital expenditure requirements towards acquiring machinery in the manufacturing unit
2. Funding the incremental working capital requirements of the Company
3. Repayment and/or prepayment, in part or full, of certain of the outstanding borrowings availed by the Company
4. General Corporate Purposes
Company Contact Details
Asston Pharmaceuticals Limited
4th Floor, Office No. A-431 Balaji Bhavan,
Plot No 42A Sector-11 CBD Belapur,
Navi Mumbai, Thane
Navi Mumbai, Maharashtra, 400614
Phone: +91 22 49731411
Email: info@asstonpharmaceuticals.com
Website: http://www.asstonpharmaceuticals.com/
Registrar Contact Details
Lead Mangers
Sobhagya Capital Options Ltd
Market Maker
JSK Securities and Services Private Limited